The main challenges in the management of MCL patients are tightly correlated with the biological diversity of the disease and its heterogeneous clinical presentation, that both underlie the existence of various morphological subtypes, distinct IGHV and TP53 mutational status, together with the absence of actionable genetic variants that could define a common therapeutically amenable target for this disease. This evidence concerns the gene TP53 and mantle cell lymphoma.